A review of 10 articles finds that nearly 9% of adverse event (AE) reports with biologics used to treat psoriasis were gastrointestinal (GI)-related and suggests that the relative rate may be higher ...

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how clinicians use primary versus secondary loss of efficacy to guide biologic ...

Among patients with inflammatory bowel disease (IBD), overlapping biologic therapy was common during medication switches and was not associated with a higher risk for infection than nonoverlapping ...